Formation of donor-specific human leukocyte antigen antibodies after kidney transplantation: Correlation with acute rejection and tapering of immunosuppression

Transplantation

Volumn 75, Issue 6, 2003, Pages 871-877

  Van Der Mast, Barbara J ^a   Van Besouw, Nicole M ^a   Witvliet, Marian D ^b   De Kuiper, Petronella ^a   Gregoor, Peter Smak ^a   Van Gelder, Teun ^a   Weimar, Willem ^a   Claas, Frans H J ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN; HLA ANTIBODY; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY SCREENING; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; FLOW CYTOMETRY; GRAFT REJECTION; HUMAN; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALE; OLIGURIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPLEEN CELL; TIME SERIES ANALYSIS;

ACUTE DISEASE; ADULT; AGED; AUTOANTIBODIES; AZATHIOPRINE; B-LYMPHOCYTES; CYCLOSPORINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; T-LYMPHOCYTES;

EID: 0037468698     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000054840.70526.D0     Document Type: Article

References (32)

1. Feucht HE, Opelz G. The humoral immune response towards HLA class II determinants in renal transplantation [editorial]. Kidney Int 1996; 50(5): 1464.
2. Martin S, Taylor CJ. The immunologically sensitised renal transplant recipient: the impact of advances in technology on organ allocation and transplant outcome. Transplant Rev 1999; 13: 40.
3. Nunez G, McPhaul JJ Jr, Stastny P. Characterization of B cell antibodies in kidney transplant recipients. Transplantation 1983; 35(5): 446.
4. Lordon RE, Stelzer GT, Ferrone S. The early posttransplant prognosis of acute renal allograft rejection as determined by detection of cytotoxic antibodies to lymphoid B cell lines. Transplantation 1984; 38(5): 493.
5. Martin S, Dyer PA, Mallick NP, et al. Post-transplant antidonor lymphocytotoxic antibody production in relation to graft outcome. Transplantation 1987; 44: 50.
6. Christiaans MH, Overhof-de Roos R, Nieman F, et al. Donor-specific antibodies after transplantation by flow cytometry: relative change in fluorescence ratio most sensitive risk factor for graft survival. Transplantation 1998; 65(3): 427.
7. McKenna RM, Takemoto SK, Terasaki PI. Anti-HLA antibodies after solid organ transplantation. Transplantation 2000; 69(3): 319.
8. Ting A, Morris PJ. Development of donor-specific B lymphocyte antibodies after renal transplantation. No correlation with graft outcome. Transplantation 1979; 28(1): 13.
9. Muller-Steinhardt M, Fricke L, Kirchner H, et al. Monitoring of anti-HLA class I and II antibodies by flow cytometry in patients after first cadaveric kidney transplantation. Clin Transplant 2000; 14(1): 85.
10. Supon P, Constantino D, Hao P, et al. Prevalence of donor-specific anti-HLA antibodies during episodes of renal allograft rejection. Transplantation 2001; 71(4): 577.
11. Sintchak MD, Fleming MA, Futer O, et al. Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell 1996; 85: 921.
12. Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 1996; 10: 77.
13. Smith KGC, Isbel NM, Catton MG, et al. Suppression of the humoral immune response by mycophenolate mofetil. Nephrol Dial Transplant 1998; 13: 160.
14. Smak Gregoor PJ, van Gelder T, van Besouw NM, et al. Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction. Transplantation 2000; 70(1): 143.
15. Lim VL, Gumbert M, Garovoy MR. A flow cytometric method for the detection of the development of antibody to Orthoclone OKT3. J Immunol Methods 1989; 121(2): 197.
16. Brand A, van Leeuwen A, Eernisse JG, et al. Platelet transfusion therapy. Optimal donor selection with a combination of lymphocytotoxicity and platelet fluorescence tests. Blood 1978; 51(5): 781.
17. Kissmeyer-Nielsen F, Olsen S, Petersen VP, et al. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet 1966; 2(7465): 662.
18. Ting A. Positive crossmatches: when is it safe to transplant? Transpl Int 1989; 2(1): 2.
19. Monteiro F, Buelow R, Mineiro C, et al. Identification of patients at high risk of graft loss by pre- and posttransplant monitoring of anti-HLA class I IgG antibodies by enzyme-linked immunosorbent assay. Transplantation 1997; 63(4): 542.
20. Kerman RH, Susskind B, Kerman DH, et al. Anti-HLA antibodies detected in posttransplant renal allograft recipient sera correlate with chronic rejection. Transplant Proc; 29(1-2):1515, 1997.
21. Suciu-Foca N, Reed E, D'Agati VD, et al. Soluble HLA antigens, anti-HLA antibodies, and antiidiotypic antibodies in the circulation of renal transplant recipients. Transplantation 1991; 51(3): 593.
22. Schonemann C, Groth J, Leverenz S, et al. HLA class I and class II antibodies: monitoring before and after kidney transplantation and their clinical relevance. Transplantation 1998; 65(11): 1519.
23. Halloran PF, Schlaut J, Solez K, et al. The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class-I-like antibody. Transplantation 1992; 53: 550.
24. Costa AN, Scolari MP, Iannelli S, et al. The presence of posttransplant HLA-specific IgG antibodies detected by enzyme-linked immunosorbent assay correlates with specific rejection pathologies. Transplantation 1997; 63(1): 167.
25. Scornik JC, Salomon DR, Lim PB, et al. Posttransplant antidonor antibodies and graft rejection. Evaluation by two-color flow cytometry. Transplantation 1989; 47(2): 287.
26. Lobo PI, Spencer CE, Stevenson WC, et al. Evidence demonstrating poor kidney graft survival when acute rejections are associated with IgG donor-specific lymphocytotoxin. Transplantation 1995; 59(3): 357.
27. Worthington JE, Thomas AA, Dyer PA, et al. Detection of HLA-specific antibodies by PRA-STAT and their association with transplant outcome. Transplantation 1998; 65(1): 121.
28. Smith JD, Danskine AJ, Rose ML, et al. Specificity of lymphocytotoxic antibodies formed after cardiac transplantation and correlation with rejection episodes. Transplantation 1992; 53(6): 1358.
29. al-Hussein KA, Shenton BK, Bell A, et al. Characterization of donor-directed antibody class in the post-transplant period using flow cytometry in renal transplantation. Transpl Int 1994; 7(3): 182.
30. Susal C, Opelz G. Kidney graft failure and presensitization against HLA class I and class II antigens. Transplantation 2002; 73(8): 1269.
31. Lazda VA. Identification of patients at risk for inferior renal allograft outcome by a strongly positive B cell flow cytometry crossmatch. Transplantation 1994; 57(6): 964.
32. Piazza A, Poggi E, Borrelli L, et al. Impact of donor-specific antibodies on chronic rejection occurrence and graft loss in renal transplantation: posttransplant analysis using flow cytometric techniques. Transplantation 2001; 71(8): 1106.